

Therapeutics Collection: Part 1

[Follow this link to retrieve all documents](#)

GENERAL

1. Features, Evaluation and Treatment Coronavirus COVID-19. StatPearls-NCBI Bookshelf, StatPearls Publishing, Treasure Island, FL: Jan.2020.
Features.Evaluation.Treatment.COVID-19.StatPearls

1a. Coronavirus disease 2019 (COVID-19). UpToDate. Accessed 1.Apr.2020.
COVID-19.utd.2020-03-31

2. Treatment of COVID-19: old tricks for new challenges. Critical Care 2020; 24:91.
Treatment.COVID-19.Old tricks.New challenges.CritCare2020

3. Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Publica. 2020; 44: e40.
ClinTrialsDrugReposition.COVID19 treatment.PanAmJPubHlth.Mar2020

4. Drug targets for corona virus: A systematic review. Indian Journal of Pharmacology. 52.1 2020: 56.
DrugTargetsCoronaVirus.SystematicReview.IndJPharmacol.2020

THERAPY

5. Treatment for severe acute respiratory distress syndrome from COVID-19. Lancet Respiratory Medicine 2020.
Tx.Severe ARDS.COVID-19.Lancet2020

6. Hydroxychloroquine: Drug information. UpToDate. Accessed 26.Mar.2020.
HydroxychloroquineDrug information.LexiComp.utd.Mar2020

7. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International Journal of Antimicrobial Agents 2020: 105949.
Hydroxychloroquine.Azithromycin.COVID-19.Open-labelNon-RCT.IntJAntimicroAgents2020

8. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.

International Journal of Antimicrobial Agents 105932 2020.

Chloroquine.Hydroxychloroquine.COVID-19.IntJAntimicrobAgent2020

9. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience Trends 2020.

ChloroquinePhos.Efficacy.COVID19-AssocPneumonia.ClinStudies.BiosciTrends2020

10. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. Journal of Critical Care 2020.

Efficacy.Safety.Chloroquine.COVID19.JCritCare.2020

11. Choice of drug therapy in primary (essential) Hypertension. UpToDate. Accessed 26.Mar.2020.

COVID19.ACE Inhibitors.ARBs.utd.Mar2020

12. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? Journal of the American Medical Association 2020.

COVID19.ACEIs.ARBs.CVDEvidence.jama_2020

12.a Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19.

New England Journal of Medicine. Mar30.2020

RAASInhibs.COVID19.NEJM.2020Mar30

12a. Renin-Angiotensin System Blockers and the COVID-19

Pandemic.Hypertension.2020.

RAS Blocker .COVID-19 Pandemic.Hypertension2020

12b. Angiotensin Receptor and COVID-19. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. Journal of Travel Medicine.

AngiotensinReceptor.COVID19.JTravelMed.2020

13. Repurposing Dupilumab May Treat Advanced COVID-19 Patients with Severe Acute Respiratory Syndrome by Mitigating Cytokine Storm. OSF Preprints, 19 Mar. 2020.

Dupilimab.COVID.ARDS.osf2020

14. Remdesivir (United States: Investigational agent; refer to Prescribing and Access Restrictions): Drug information. UpToDate Accessed 26.Mar.2020.

Remdesivir.US.Investig agent.Drug info.utd.2020

14a. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality.

International Journal of Antimicrobial Agents.2020

CytokinReleasSyndrom.COVID19.Tocilizumab.IntJAntimicrobAgents.2020

15. Should patients stop their biologic treatment during the COVID-19 pandemic. J

Dermatological Treatment 2020

BiologicTreatmentDuringCOVID19Pandemic.J DermTreat2020

16. The convalescent sera option for containing COVID-19. The Journal of Clinical Investigation 130.4 2020.

ConvalescentSera.COVID-19.JClinInvest.2020

Web Links

1. **FAQs about Respiratory Protection**
2. **Canadian Pharmacists Association – Covid information and resources**
3. **Compounding Alcohol-Based Hand Sanitizer During COVID-19 Pandemic**
4. **Oncology Nursing Society (ONS) Interim Guidelines during the COVID-19 Pandemic**
5. **FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic -Guidance for Industry, Investigators, and Institutional Review Boards**
March 2020, Updated on April 2, 2020
6. **Audio Interview: Practical Measures to Help Prevent Covid-19**
In this audio interview conducted on March 25, 2020, the editors discuss transmission of SARS-CoV-2 and how to prevent it, particularly for health care workers.

COVID-19 Global Cases Dashboard- Johns Hopkins University

IHME Covid19 State Data

